QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Successful Delivery of Nicotine Within Minutes in Edible Nicotine Study

Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced that within minutes after dosing in an animal in vivo study, it has successfully delivered nicotine in an edible form into blood plasma. Per the update, Lexaria’s DehydraTECH™ technology delivered nicotine with 90.2% greater delivery than the concentration-matched control formulation by the 10-minute mark and substantially greater absorption levels than the control formulation at all time intervals in the study. The company contracted a third-party laboratory to conduct the study which concentrated on detailed analysis of absorption over a 60-minute period. Lexaria’s in vitro laboratory, in vivo animal and human clinical absorption studies have all demonstrated quicker and more effective delivery of substances such as nicotine and cannabinoids. The company is continuing its focus on progressing both its R&D and commercialization initiatives with its DehydraTECH™ technology platform.

“Lexaria’s DehydraTECH™ breakthrough technology is demonstrating significant effectiveness in delivering nicotine into the bloodstream much more rapidly than we thought possible, and at levels approaching two times more effective than controls,” Lexaria CEO Chris Bunka stated in the news release. “If we can develop viable ingestible alternatives to cigarette smoking we could help hundreds of millions of people avoid many of the disease states associated with smoking and I cannot imagine a more rewarding destiny bestowed upon Lexaria Bioscience Corp.”

To view the full press release, visit http://ibn.fm/t2qir

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php